Trump’s Pharma Tariff Threat Looms: What it could mean for Indian drug makers

Indian pharma companies are confronting fresh policy headwinds following a pledge by US President Donald Trump to impose burdensome tariffs on drug imports.

Speaking at a National Republican Congressional Committee dinner in Florida, Trump said the move was aimed at encouraging foreign drug manufacturers to bring their business to America.

Though the policy has not yet been formally notified, the threat is already making its impact felt especially on Indian exporters who are highly dependent on the US generics market.

India and China are the two biggest exporters of generic drugs to the US. Any tariff-based entry barrier would be detrimental to cost competitiveness, margins, and market share for Indian pharma firms that rely significantly on the US for revenues as well as profitability.

Why the US market is crucial for Indian pharma

The United States accounts for over 30–40 per cent of top-line revenues for major Indian players such as Sun Pharma, Cipla, Lupin, Dr Reddy's, and Zydus Lifesciences. The players heavily invested in USFDA-approved facilities, Abbreviated New Drug Application (ANDA) dossiers, and complex generics over the last decade.

Any disruption whether tariff, inspection, or new trade policy—can negatively impact their revenues. Companies with higher exposure in injectables, oral solids, or specialty segments in the US are particularly exposed, as the pricing tensions in the market are already taut.

Margin pressure may rise again

Indian pharma players have been witnessing reprieve from price erosion and US product launches in the past few quarters. A new tariff regime will reverse the trend. Experts opine that any cost passed on to the supply chain would dent gross margins, especially for players with smaller economies of scale or price-sensitive products.

Additionally, compliance and regulatory costs may increase if firms need to move more activities to the US or establish packaging/localisation facilities there to respond to tariffs.

Who would be affected most?

• Sun Pharma and Cipla have strong US exposure in generics and complex molecules, including the respiratory and dermatology segments.
• Lupin recently accelerated US filings but is still sensitive to pricing.
• Zydus Lifesciences could be affected in injectables and biosimilars.
• Gland Pharma, which has exports of injectable formulations to the US and Europe, can be vulnerable to twin pressure from tariffs and overhangs prevailing on promoter issues.

What to expect in the future

Investors must monitor closely: -

• Official statements or executive orders of the US government
• Reactions from the Indian government and trade bodies
• Q4FY25 earnings management commentary on export strategy and margin outlook
• Any alteration of FDA approvals or launch dates in the US pipeline

Until policy clarity is reached, Indian pharma stocks may remain volatile, and analysts may re-estimate earnings depending on the structure and timing of the proposed tariffs.